In our recent article, we presented data from patients with breast cancer receiving endocrine therapy and FMD cycles (patients #1–#24) and showed that the FMD effectively lowered the serum levels of growth-promoting and pro-oncogenic factors, such as insulin, IGF1 and leptin, with IGF1 and leptin remaining low for weeks beyond the FMD period [2]. This evidence concerns the gene IGF1 and breast carcinoma.